Swedish start-up Atrogi has enrolled the first patient in its Phase Ia/b study of ATR-258, a novel b2adrenoceptor agonist for the treatment of type 2 diabetes and comorbidities. Conducted in Mannheim, Germany by Clinical Research Services (CRS), the trial is expected to be completed by April 2023 with the final report in June 2023. The […]
